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home residents 65 years or older from four states. New typical and atypical users in
nursing homes were followed for up to six month after the exposure without cen-
soring. The risk of death wasmodeled using Cox proportional model and extended
Cox hazardmodel stratified onmatched pairs based on propensity score.RESULTS:
The unadjusted mortality rate was 19.22% for atypical antipsychotic users and
24.27 % for typical antipsychotic users. Cox proportional hazard model revealed
significant increased risk of death [Hazard Ratio (HR) 1.35, 95%; Confidence Interval
(CI) 1.30- 1.63] among typical users when compared to atypical users. The extended
Coxmodel, used due to the violation of proportional hazards assumption, revealed
that risk of death is twice greater among typical antipsychotic users during the
initial 40 days after the start of antipsychotic treatment [HR 2.06, 95%; CI 1.82-2.32]
when compared to atypical users. However, no significant differences were found
after 40 days of antipsychotic exposure. CONCLUSIONS: The use of typical antipsy-
chotic agents was associated with increased risk of death among aged dual eligible
beneficiaries when compared to atypical use, especially within 40 days of treat-
ment, possibly due to their underlying health status.
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THE INFLUENCE OF COMORBID ANXIETY ON MEDICATION USE AND SERVICE
UTILIZATION AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER:
RESULTS FROM A RETROSPECTIVE CLAIMS DATABASE
Wu CH, Farley J
University of North Carolina, Chapel Hill, NC, USA
OBJECTIVES: The objectives are to estimate the prevalence of comorbid anxiety
and to compare the influence of comorbid anxiety on medication adherence and
health resource utilization among privately insured individualswithMajor Depres-
sive Disorder (MDD).METHODS: Patients withMDD between 18 and 64 years of age
newly initiating an antidepressant between July 1, 2005, and December 31, 2006,
were identified from the MarketScan Commercial Claims database. MDD patients
were defined as having comorbid anxiety if theywere concurrently diagnosedwith
generalized anxiety disorder (GAD), panic disorder (PD), or social anxiety disorder
(SAD).We used a retrospective cohort study design to compare the effect of comor-
bid anxiety disorder on antidepressant adherence measured as proportion of days
covered (PDC), adherence (PDC 80% ), and presence of emergency room (ER) visit
or inpatient encounters. Student t-testswere used to compare adherence rates and
logistic regressions were used to compare health service utilization (ER visit and
hospitalization) between patients with and without comorbid anxiety disorder.
RESULTS: Of 71,467 adults with MDD, 8.4% had GAD, 7.1% had PD, and 6.1% had
SAD. The mean value of PDC among the study population was 0.56. MDD patients
with comorbid anxiety had significantly higher PDC value than patients without
comorbid anxiety (0.58 vs. 0.56, p0.01). MDD patients with comorbid anxiety were
more likely to havemental health-related ER visits than patientswithout comorbid
anxiety after adjusting for age, gender, Charlson comorbidity index, and covariates
associated with prior health care utilization (OR1.16, 95%CI1.10-1.22). However,
there was no difference between patients with and without comorbid anxiety in
the probability of hospitalization. CONCLUSIONS: MDD patients with comorbid
anxiety had higher mental health-related ER visits. Clinicians treating patients
with MDD should consider the role of comorbid anxiety on medication adherence
and clinical outcomes.
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PERFORMANCE OF RISK ADJUSTMENT SCALES IN PREDICTING RISK OF
HOSPITALIZATION AMONG DEMENTIA PATIENTS: A MEPS STUDY
Bhowmik D, Mehta S, Chitnis A, Dwibedi N, Kamble P, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: To evaluate performances of various risk adjustment scales in pre-
dicting risk of hospitalization in patients diagnosed with dementia. METHODS:
This cross-sectional study was conducted using the household and medical pro-
vider component files of Medical Expenditure Panel Survey (MEPS) data from 2000
to 2003 (panel 5, 6, and 7). Dementia patients were identified using cccodex and
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-
9CM) codes, and all cause hospitalizations were recorded from the inpatient files.
The risk adjustment scales evaluated in this study were- diagnosis based scales
(identified using ICD-9CM codes): D’Hoore’s adaptation of Charlson comorbidity
index (CCI), and Elixhauser comorbidity algorithm; and prescription based scales
(identified using national drug codes): chronic disease scores (CDS-1 and CDS-2).
Logistic regression models were constructed with all-cause hospitalization as bi-
nary outcome, adjusting for demographic, socio-economic (insurance, income,
geographic region), and perceived health status covariates, and risk adjustment
algorithms. Performance of themodels in predicting hospitalizationwasmeasured
by c-index. RESULTS: Total 392 dementia patients were identified from the house-
hold component files during the study period. Most of the patients were male
(68.58%), white (54.11%), elderly (mean age 73 years), and from a low income family
(59.85%); and almost half of them had an inpatient visit (46.70%). Baseline logistic
model with the covariates only predicted hospitalization risk reasonably well (c
0.602). Performance of risk adjustment models after adjusting for covariates were
as follows- D’Hoore: c 0.688, Elixhauser: c 0.691, CDS-1: c 0.666, CDS-2: c
0.733, CDS-1D’Hoore: c 0.687, CDS-1Elixhauser: c 0.709, CDS-2D’Hoore: c
0.752, and CDS-2Elixhauser: c 0.757. CONCLUSIONS: Diagnosis based scales
performed better than CDS-1 scale in predicting hospitalization. CDS-2 which is a
comorbidity algorithm modified from CDS-1 to efficiently model healthcare utili-
zation and cost performed superiorly. Among the combinations of diagnosis and
prescription based scales CDS-2Elixhauser predicted hospitalization risk most
efficiently.
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THE PROFILE OF IMPAIRMENTS TO ATTENTION AND EPISODIC RECOGNITION
MEMORY IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE
Wesnes K1, Lenderking WR2
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OBJECTIVES: Automated tests can assess aspects of cognitive function which can-
not be assessed using traditional non-automated techniques. To build on previous
findings that patients with minimal cognitive impairment show slower informa-
tion retrieval (Nicholl et al, 1995), the present analysis compared 74 patients with
amnestic Mild Cognitive Impairment (MCI) to healthy controls (n1409), and pa-
tients with mild, moderate and moderately-severe Alzheimer’s disease (AD;
n764). METHODS: Three CDR System tests of attention were administered (digit
vigilance, simple and choice reaction time) and two episodic memory tests (word
and picture recognition). For attentionPower of Attention (the ability to focus at-
tention) andContinuity of Attention (the ability to sustain attention)were used. For
recognition, the abilities to correctly identify previous stimuli and reject novel
stimuli were analysed, as was speed of response. RESULTS: For Power of Attention,
and Word and Picture Recognition Speed, there was a clear continuum of decline
from normals through AD. For Continuity of Attention, Word Recognition Accu-
racy, and the ability to recognise previous pictures, MCI subjects demonstrated
preserved functioning equivalent to controls. For the ability to reject novel pic-
tures, MCI patients showed deficits comparable to moderate AD patients. The abil-
ity to reject novel pictures is related to activity in the cingulate gyrus, and the
impairment in MCI suggests disruptions to this area, which may have conse-
quences for neurogenesis. Overall, the pattern of decline is not consistent across all
cognitive functions assessed. CONCLUSIONS: These findings will be discussed in
terms of the likelihood that amnestic MCI is a prodrome of AD, whichmay be the
case for episodic memory as assessed by delayed word recall, but not necessar-
ily for aspects of episodic recognitionmemory or the ability to sustain attention.
This may have implications for treatment of early disease, as well as prevention
strategies.
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COMPARATIVE EFFECTIVENESS STUDY OF RISPERIDONE LONG-ACTING
INJECTABLE: THE USE OF DYNAMIC EXPOSURE METHODOLOGY FOR RISK
SHARING AGREEMENT
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Risperidone long-acting injectable (R-LAI) was the first of the ‘atypical’ antipsy-
chotic drugs with delayed release to be marketed worldwide for the treatment of
schizophrenia. This strategy was envisaged to deliver a primary advantage over
conventional oral drugs but could not be demonstrated ahead of marketing ap-
proval as R-LAI was mainly assessed against placebo for that purpose. A risk-
sharing agreement was reached between the manufacturer and the French
National Health Pricing Authority – The Economic Committee on Health Care Prod-
ucts (CEPS), under which coverage would be ensured following demonstration of
cost minimization in real terms. OBJECTIVES: To assess whether R-LAI use was
associated with a decreased risk of hospitalization and provide data for risk-shar-
ing agreement and coverage.METHODS:A cohortwith a ‘dynamic exposure’meth-
odology was used to assess the relative effectiveness of R-LAI. A cohort of adult
patients with schizophrenia was recruited from 177 psychiatric hospitals across
France and observed naturalistically over 12 months. A 3-month granularity was
used for treatment characterization. The relative rate of hospitalization was as-
sessed using a Poisson multiple regression model for auto-correlated data (SAS-
GENMOD). Results were adjustedwith propensity scores using potential confound-
ers of R-LAI use vs. non-use, including history of hospitalization, severity of
schizophrenia, and patterns of antipsychotic use. RESULTS: The cohort consisted
of 1859 patients with 454 person years of R-LAI use, and 1306 person years of R-LAI
non-use. R-LAI use was associated with an adjusted rate ratio of hospitalization of
0.66 (95% CI: 0.460.96) when compared to non-use and 0.53 (95% CI: 0.320.88)
when compared to typical LAI antipsychotics. This was found to be associatedwith
better compliance in patientswith a history of recurrent hospitalization, and there-
fore compensated for the costs of treatment. CONCLUSIONS: A cohort with dy-
namic-exposure methodology established a successful risk-sharing agreement for
a new treatment for schizophrenia.
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CLINICAL EFFECTIVENESS ANALYSIS OF NALTREXONE VERSUS ACAMPROSATE
AND PLACEBO IN ALCOHOL DEPENDENT PATIENTS TREATED WITH
PSYCHOTHERAPY
Jarosz J, Miernik K, Wachal M, Walczak J
Arcana Institute, Cracow, Poland
OBJECTIVES: The objective of this study is to assess the clinical effectiveness of
naltrexone versus acamprosate and placebo in alcohol dependent patients receiv-
ing psychotherapy. METHODS: Analysis was conducted in accordance with the
principles of systematic review, based on the Cochrane Collaboration guidelines
and the guidelines of the Polish Agency for Health Technology Assessment. Calcu-
lations were performed using the StatsDirect® 2.6.8 statistical package. The ex-
tended evaluation of safety based on sources other than RCTs was performed.
RESULTS: In the light of the analysis carried out it can be concluded that adminis-
tered orally plus psychotherapy for alcohol-dependent patients results in a higher
clinical effectiveness and comparable safety profile in comparison with acampro-
sate for a 1-year-long-observation treatment and placebo for both a short (12-16
weeks) and medium-term observation treatment. Statistical significances in favor
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of the intervention under evaluation were found both in the percentage of patients
maintaining total abstinence as well as in the percentage of relapsed patients.
Statistically significant in favor of naltrexone treatment when assessing too such
endpoint as alcohol craving intensity assessment for the NAL/PSY vs ACA/PSY
analysis in a long treatment period and for the NAL/PSY vs PL/PSY analysis in a
short term.Long-term results (52 weeks) of the analysis quoted indicate on a com-
parable clinical efficacy (no statistical significance of results obtained) of the use of
naltrexone and placebo in the group of alcohol-dependent patients undergoing
psychotherapy.The adverse events related to naltrexone treatment are usually
mild and transient. The most frequent ones are: headaches, sleep disorders, anx-
iety, nervousness, gastrointestinal disorders such as abdominal pain, nausea,
vomiting. CONCLUSIONS: Summing up, the results of the analysis carried univo-
cally prove that naltrexone administered in a 50mg dose a day is an effective and
safe drug in the treatment of alcohol dependent patients who additionally undergo
a psychotherapy.
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IMPACT OF ADHERENCE TO FIRST THERAPY ON THE RISK OF
ANTIDEPRESSANT SWITCHING
Jung SY, Shin S, Song H, Park J, Ahn J
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OBJECTIVES: To assess the impact of adherence to first antidepressant (AD) ther-
apy on risk of AD switching, using nationwide claims database. METHODS: Using
the Korean Health Insurance Review & Assessment Service (HIRA) claims database
(2006-2008), newly diagnosed depression patientswho aged 18-84,withoutmedical
visit due to depression (ICD 10F06.3, F31.3, F31.4, F32, F33, F34.1, F38.1, F41.2)
within 6 months before the first observed prescription of ADs between Jul 2006 to
Jun 2007 (18 months index period), and with at least 3 psychiatric visits within 3
months from index date were identified. ADs were categorized as tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and new antide-
pressants (NADs). For each AD category, adherence by 90 days post-index period
Medication possession ratio (MPR) was estimated. Switching was defined prescrip-
tion of different class of AD therapy from last AD regimen. Time to first switching
was assessed. Cox proportional hazards model was used to investigate the rela-
tionship between adherence to AD and time to switch. RESULTS: A total of 88,079
patients satisfied the selection criteria, among which mean age of 45.2 years and
67.3% of women.When assessed AD therapywithin 90 days from index date, 31.3%
of the patients prescribed SSRI monotherapy, 16.4% prescribed TCAmonotherapy,
and 15.2% prescribed SSRINAD polytherapy. Overall rate of switching was 38.1%.
When adjusted for age, gender, and AD regimen, patients with higher adherence
(MPR75%) showed lower rate of switching (adjusted OR0.93[95% CI0.91-0.95]).
CONCLUSIONS: Switching AD therapy can be inferred as indicator of insufficient
effectiveness or adverse drug reaction. Improving adherence to AD therapy in
newly diagnosed depression patients is important to prevent the switching AD
therapy afterwards.
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CHARACTERISTICS OF PATIENTS IN COMMUNITY BEHAVIORAL HEALTH
ORGANIZATIONS RECEIVING TWO INJECTABLE FORMS OF ATYPICAL
ANTIPSYCHOTIC MEDICATIONS AS COMPARED WITH OTHER
ANTIPSYCHOTICS
Mark T1, Panish J2, Mao L2, Montejano LB3, Dirani R4, Fastenau J2, Starr HL2
1Thomson Reuters, Washington, DC, USA, 2Johnson & Johnson, Titusville, NJ, USA, 3Thomson
Reuters, Cambridge, MA, USA, 4Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA
OBJECTIVES: To describe characteristics of patients with schizophrenia receiving
treatment with atypical injectable antipsychotics paliperidone palmitate and ris-
peridone long-acting as compared to other antipsychotics therapy at community
behavioral health organizations (CBHOs) in the United States.METHODS: A longi-
tudinal, noninterventional observational registry, Research and Evaluation of An-
tipsychotic Treatment in Community Behavioral Health Organizations OUTcomes
(REACH OUT) is collecting information on use of paliperidone palmitate, risperi-
done long-acting therapy (LAT), and other antipsychotics by patients with schizo-
phrenia or bipolar type I disorder receiving treatment at CBHOs. Patients are fol-
lowed for 1 year, with assessments at baseline, 6, and 12 months. Sites use a
Web-based data-collection tool to enter patient self-reports, interviewer assess-
ments, and medical record abstractions. RESULTS: At time of analysis, baseline
patient interview data from 114 patients with schizophrenia were collected at 10
sites in the following cohorts: 44% paliperidone palmitate injections, 33% risperi-
done injections, and 23% other antipsychotics. Patients in the paliperidone palmi-
tate or risperidone LAT cohorts were older, on average, than those receiving other
antipsychotics: paliperidone palmitate, 41.2 years; risperidone LAT, 43.0; other an-
tipsychotics, 35.0. Mean age at first psychiatric hospitalization was older for pali-
peridone palmitate (23.1) and risperidone LAT (24.4) than for other antipsychotics
(20.1). Patients receiving the two injectable antipsychotics were more likely to be
male (paliperidone palmitate, 70.0%; risperidone LAT, 73.7%; other antipsychotics,
69.2%) and single/never married (paliperidone palmitate, 78.0%; risperidone LAT,
78.9%; other antipsychotics, 69.2%). Patients treated with atypical antipsychotic
injectionswere less likely to have private health insurance (paliperidone palmitate,
6.0%; risperidone LAT, 0.0%; other antipsychotics, 19.2%) and more likely to have
Medicare (paliperidone palmitate, 60.0%; risperidone LAT, 60.5%; other antipsy-
chotics, 23.1%) or Medicaid (paliperidone palmitate, 82.0%; risperidone LAT, 78.9%;
other antipsychotics, 46.2%). CONCLUSIONS: Results suggest that patients in CB-
HOs receiving paliperidone palmitate and risperidone injections may differ from
patients receiving other antipsychotics io sociodemographics.
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PREVALENCE OF ANTICHOLINERGIC DRUG PRESCRIBING IN ELDERLY
OUTPATIENTS WITH DEMENTIA
Bhattacharya R, Chatterjee S, Aparasu R
University of Houston, Houston, TX, USA
OBJECTIVES: Anticholinergic medications, though frequently used in the elderly
population, are associated with cognitive impairment and use of these agents is a
concern in dementia patients. This study examined the prevalence and predictors
of anticholinergic prescribing in elderly outpatients with dementia. METHODS:
Data from 2006–2007 National Ambulatory Medical Care Survey (NAMCS) and the
outpatient National Hospital Ambulatory Medical Care Survey (NHAMCS) were
combined to analyze elderly (65 years or older) patient visits for dementia (ICD-
9-CM codes-290.XX, 291.2, 294.XX, 331.XX, 046.1 and 046.3). Anticholinergic drugs
were identified using a preexisting scale, the Anticholinergic Drug Scale (ADS),
which classified anticholinergic drugs into four levels in increasing order of their
anticholinergic activity. Descriptive analysis was used to evaluate prevalence pat-
terns and multiple logistic regression was conducted to examine the factors asso-
ciated with prescribing of medications with marked anticholinergic activity (Level
2 or Level 3). RESULTS: According to the 2006-2007 NAMCS and NHAMCS data,
there were a total of 6.8 million (95% Confidence Interval (CI) 5.27-8.44 million,
0.32%) ambulatory care visits for dementia. Nearly 43% (95% CI 35.24%-50.48%) of
all elderly dementia patient visits involved prescribing of at least one anticholin-
ergic drug; 36.76% of the above visits involved Level 1 medications, 10.85% of visits
involved Level 2 or Level 3 medications. While age (75-84 years; Odds Ratio (OR)
0.26, 95% CI0.08-0.85) and acetylcholine esterase inhibitor use (OR 0.21, 95% CI
0.07-0.65) increased the likelihood of prescribing medications with marked anti-
cholinergic activity, total number of medications prescribed also (OR 1.41, 95% CI:
1.81-1.67) increased the likelihood of these prescriptions.CONCLUSIONS:Over 10%
of elderly dementia visits involved prescribing of medications with marked anti-
cholinergic activity. Given the severe cognitive adverse events, there is strong need
to optimize anticholinergic drug prescribing in elderly outpatients with dementia.
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IMPACT OF COGNITIVE IMPAIRMENT ON FUNCTIONING, MEDICAL RESOURCE
UTILIZATION, ADHERENCE AND HEALTH-RELATED QUALITY OF LIFE IN
PATIENTS WITH SCHIZOPHRENIA
Lin FJ1, Bhor M2, Hass S2, Perry R3, Kay S3
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OBJECTIVES: To examine the influence of cognitive impairment on functioning,
medical resource utilization, adherence, and health-related quality of life (HRQoL)
in patients with schizophrenia. METHODS: Data analyzed were from a cross-sec-
tional study of patients with schizophrenia and their physicians (2005 Adelphi US
Psychoses XI Disease Specific Programme). Outpatient schizophrenia patients aged
18 years with 4 physician encounters in the past 12 months were identified.
Physicians evaluated their patients’ cognitive impairment, positive and negative
symptoms, functioning (employment status, presence of a caregiver, global assess-
ment of functioning (GAF) scale, Likert scales measuring overall function and abil-
ity to meet own basic needs), adherence, and resource utilization. HRQoL (EQ-5D
tariff and visual analog scale (VAS), Likert scales measuring overall sense of well
being, overall life satisfaction, and satisfaction with relationships) and adherence
data were collected directly from patients. Multivariate analyses were used to ex-
amine the predictors for each outcome variable. Covariates included patients’ de-
mographics and their comorbidities. RESULTS: Eighty one percent of the 839
schizophrenia patients had cognitive impairment. A higher level of cognitive func-
tion was associated with higher overall functioning and GAF scores, improved
ability tomeet basic needs, being employed, not having a caregiver, fewer ER visits,
greatermedication adherence, better HRQoL (EQ-5D and VAS scores), overall sense
of well-being, and higher satisfaction with life and social relationships (p0.05).
The severity of positive and negative symptoms was positively associated with
poorer functioning, number of outpatient visits, and poorer HRQoL. Severe positive
symptoms also predicted more hospitalizations and poorer adherence (p0.05).
Cognitive impairment was associated with fourteen outcomes, while positive and
negative symptoms predicted nine and six outcomes respectively. CONCLUSIONS:
Cognitive impairment in schizophrenia patients is significantly associated with
a number of measures of disease burden, which can substantially increase the
impact of the disease beyond that associated with only positive and negative
symptoms.
Mental Health – Cost Studies
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THE BUDGET IMPACT ANALYSIS OF NALTREXONE IN THE TREATMENT OF
ALCOHOL-DEPENDENT PATIENTS IN POLAND
Walczak J, Semeniuk A, Pacocha K, Nogas G
Arcana Institute, Cracow, Poland
OBJECTIVES: The purpose was to estimate financial consequences of naltrexone
reimbursement in the treatment of alcohol-dependent patients in Poland.
METHODS: The budget impact analysis was conducted for two-years time horizon
from the public payer perspective (National Health Fund) and, additionally, form
the patient perspective. The target population consisting of the alcohol-dependent
patients, who are treated in dependent treatment centres and are eligible for nal-
trexone therapy was estimated on the basis of epidemiological data and clinical
expert’s opinion. In the analysis two scenarios were compared: present, in which
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